Biophytis Secures $20 Million for Sarcopenia Phase 3 Trial in Asia

Biophytis has entered a strategic agreement to establish a joint venture in Hong Kong, boosting its presence in Asian markets for sarcopenia treatment. The collaboration will see Biophytis join forces with Asian partners, including China's Ronghui Renhe Life Technology, to capitalize on the potential of BIO101.

With financing secured up to $20 million over three years, including $10 million in the first year, the venture aims to expedite the development and commercialization of BIO101. Biophytis will hold 29% of the venture, with the remaining 71% controlled by Asian partners. The Phase 3 trial, set for the latter half of 2026, targets approvals across Asia and Europe, involving 942 patients.